The Mab approved for clinical use are directed against 15 targets, most of which are surface cellular antigens, including such widespread cancer markers as HER1, HER2/neu, and PSMa (prostate specific membrane antigen) (Table 2). This evidence concerns the gene EGFR and cancer.